You are viewing information for the Morgantown Campus. At another location? Change your campus.

Dr. Ali Hajiran Named as Chief of Urologic Oncology

West Virginia University Medicine is proud to announce the appointment of Dr. Ali Hajiran as the new Chief of Urologic Oncology. Dr. Hajiran is a native of Wheeling, West Virginia. Dr. Hajiran completed his undergraduate degree at Wheeling Jesuit University before earning his Doctorate of Medicine from West Virginia University School of Medicine. He completed General Surgery Internship and Urologic Surgery Residency training at West Virginia University. Dr. Hajiran then completed a Society of Urologic Oncology (SUO) accredited Fellowship at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. Dr. Hajiran has authored or co-authored more than 40 peer-reviewed manuscripts and book chapters. He specializes in treating complex cases of kidney, bladder, prostate, and testicular cancers using minimally-invasive robotic and traditional surgical techniques.

"It is a great honor to appoint Dr. Hajiran to this important role. His outstanding residency and fellowship training have provided him with the skills needed to excel. It is even more special that Dr. Hajiran has come home to bring these skills to care for the people of West Virginia, a state where he grew up in" added Dr. Zaslau, Professor and Chairman, Department of Urology.

“West Virginia has one of the highest rates of newly diagnosed cancer and cancer mortality in the nation,” Hajiran said. “As a native West Virginian, I have seen firsthand the effects of cancer on our community. To be able to serve our neighbors, family and friends who are dealing with cancer in this capacity is a dream come true. For me, this position is very personal and I look forward to bringing my energy and new ideas to this role. I am committed to working with our team of dedicated professionals to deliver the highest quality cutting-edge comprehensive urologic cancer care through multidisciplinary collaboration and improving access to clinical trials here in Appalachia.”